Nicole Sheanon

Nicole Sheanon

Auto-generated profile, based on publicly available information

Nicole Sheanon

University of Cincinnati College of Medicine, Cincinnati Children's Hospital Department of Diabetes and Endocrinology, Cincinnati, Ohio, United States

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2015 in International Journal of Pediatric Endocrinology
Verified
Journal Article
Open access
PDF file
NSNicole M. Sheanon
Nicole M. Sheanon
PBPhilippe F. Backeljauw
Philippe F. Backeljauw
Turner syndrome is a chromosomal abnormality in which there is complete or partial absence of the X chromosome. Turner syndrome effects 1 in every 2000 live births. Short stature is a cardinal feature of Turner Syndrome and the standard treatment is recombinant human growth hormone. When growth hormone is started at an early age a normal adult height can be achieved. With delayed diagnosis young women with Turner Syndrome may not reach a normal height. Adjuvant therapy with oxandrolone is used but there is no consensus on the optimal timing of treatment, the duration of treatment and the long term adverse effects of treatment. The objective of this review and meta-analysis is to examine the effect of oxandrolone on adult height in growth hormone treated Turner syndrome patients. Eligible trials were identified by a literature search using the terms: Turner syndrome, oxandrolone. The search was limited to English language randomized-controlled trials after 1980. Twenty-six articles were reviewed and four were included in the meta-analysis. A random effects model was used to calculate an effect size and confidence interval. The pooled effect size of 2.0759 (95 % CI 0.0988 to 4.0529) indicates that oxandrolone has a positive effect on adult height in Turner syndrome when combined with growth hormone therapy. In conclusion, the addition of oxandrolone to growth hormone therapy for treatment of short stature in Turner syndrome improves adult height. Further studies are warranted to investigate if there is a subset of Turner syndrome patients that would benefit most from growth hormone plus oxandrolone therapy, and to determine the optimal timing and duration of such therapy.

15 October 2021 in Hormone Research in Paediatrics
Verified
Journal Article
Open access
PDF file
NSNicole Sheanon
Nicole Sheanon
DEDeborah Elder
Deborah Elder
JKJane C. Khoury
Jane C. Khoury
LCLori Casnellie
Lori Casnellie
IGIris Gutmark-Little
Iris Gutmark-Little
PBPhillipe F. Backeljauw
Phillipe F. Backeljauw
Introduction: Adult women with Turner syndrome (TS) have a high prevalence of diabetes and β-cell dysfunction that increases morbidity and mortality, but it is unknown if there is β-cell dysfunction present in youth with TS. This study aimed to determine the prevalence of β-cell dysfunction in youth with TS and the impact of traditional therapies on insulin sensitivity (SI) and insulin secretion. Methods: Cross-sectional, observational study recruited 60 girls with TS and 60 healthy controls (HC) matched on pubertal status. Each subject had a history, physical exam, and oral glucose tolerance test (OGTT). Oral glucose and c-peptide minimal modeling was used to determine β-cell function. Results: Twenty-one TS girls (35%) met criteria for prediabetes. Impaired fasting glucose was present in 18% of girls with TS and 3% HC (p value = 0.02). Impaired glucose tolerance was present in 23% of TS girls and 0% HC (p value <0.001). The hemoglobin A1c was not different between TS and HC (median 5%, p = 0.42). Youth with TS had significant reductions in SI, β-cell responsivity (Φ), and disposition index (DI) compared to HC. These differences remained significant when controlling for body mass index z-score (p values: 0.0006, 0.002, <0.0001 for SI, Φ total, DI, respectively). Conclusions: β-Cell dysfunction is present in youth with TS compared to controls. The presence of both reduced insulin secretion and SI suggest a unique TS-related glycemic phenotype. Based on the data from this study, we strongly suggest that providers employ serial OGTT to screen for glucose abnormalities in TS youth.

22 June 2023 in JCI Insight
Verified
Journal Article
Open access
PDF file
SWShana O. Warner
Shana O. Warner
YDYufei Dai
Yufei Dai
NSNicole Sheanon
Nicole Sheanon
MYMichael V. Yao
Michael V. Yao
RCRebecca L. Cason
Rebecca L. Cason
JWJason J. Winnick
Jason J. Winnick
Fasting is associated with increased susceptibility to hypoglycemia in people with type 1 diabetes, thereby making it a significant health risk. To date, the relationship between fasting and insulin-induced hypoglycemia has not been well characterized, so our objective was to determine whether insulin-independent factors, such as counterregulatory hormone responses, are adversely impacted by fasting in healthy control individuals. Counterregulatory responses to insulin-induced hypoglycemia were measured in 12 healthy people during 2 metabolic studies. During one study, participants ate breakfast and lunch, after which they underwent a 2-hour bout of insulin-induced hypoglycemia (FED). During the other study, participants remained fasted prior to hypoglycemia (FAST). As expected, hepatic glycogen concentrations were lower in FAST, and associated with diminished peak glucagon levels and reduced endogenous glucose production (EGP) during hypoglycemia. Accompanying lower EGP in FAST was a reduction in peripheral glucose utilization, and a resultant reduction in the amount of exogenous glucose required to maintain glycemia. These data suggest that whereas a fasting-induced lowering of glucose utilization could potentially delay the onset of insulin-induced hypoglycemia, subsequent reductions in glucagon levels and EGP are likely to encumber recovery from it. As a result of this diminished metabolic flexibility in response to fasting, susceptibility to hypoglycemia could be enhanced in patients with type 1 diabetes under similar conditions.

19 August 2020 in Journal of Pediatric Endocrinology and Metabolism
Verified
Journal Article
Closed access
NSNicole M. Sheanon
Nicole M. Sheanon
SBSarah J. Beal
Sarah J. Beal
JKJessica C. Kichler
Jessica C. Kichler
LCLori Casnellie
Lori Casnellie
PBPhilippe Backeljauw
Philippe Backeljauw
SCSarah Corathers
Sarah Corathers
Objectives: Turner syndrome (TS) is a complex and chronic medical condition that requires lifelong subspecialty care. Effective transition preparation is needed for successful transfer from pediatric to adult care in order to avoid lapses in medical care, explore health issues such as fertility, and prepare caregivers as adolescents take over responsibility for their own care. The objective of this study was to evaluate accuracy of knowledge of personal medical history and screening guidelines in adolescents and young adults (AYA) with TS. Methods: This was a prospective cross-sectional study of 35 AYA with TS of ages 13–22 years recruited from a tertiary care center. AYA completed questionnaires on personal medical history, knowledge of screening guidelines for TS, and the Transition Readiness Assessment Questionnaire (TRAQ). Results: Eighty percent of AYA with TS were 100% accurate in reporting their personal medical history. Only one-third of AYA with TS were accurate about knowing screening guidelines for individuals with TS. Accuracy about knowing screening guidelines was significantly associated with TRAQ sum scores (r = 0.45, p < 0.05). However, there was no association between knowledge of personal medical history and TRAQ sum scores. Conclusions: Transition readiness skills, TS-specific knowledge, and accurate awareness of health-care recommendations are related, yet distinct, constructs. Understanding of one’s personal medical history is not an adequate surrogate for transition readiness. Validated tools for general transition, like the TRAQ, can be used but need to be complemented by TS-specific assessments and content. Providers are encouraged to identify opportunities for clinical and educational interventions well in advance of starting transfer to adult care.

22 June 2021 in JCI Insight
Verified
Journal Article
Open access
PDF file
MMMary Courtney Moore
Mary Courtney Moore
SWShana O. Warner
Shana O. Warner
YDYufei Dai
Yufei Dai
NSNicole Sheanon
Nicole Sheanon
MSMarta Smith
Marta Smith
JWJason J. Winnick
Jason J. Winnick
Several studies have associated the presence of residual insulin secretion capability (also referred to as being C-peptide positive) with lower risk of insulin-induced hypoglycemia in patients with type 1 diabetes (T1D), although the reason is unclear. We tested the hypothesis that C-peptide infusion would enhance glucagon secretion in response to hyperinsulinemia during euglycemic and hypoglycemic conditions in dogs (5 male/4 female). After a 2-hour basal period, an intravenous (IV) infusion of insulin was started, and dextrose was infused to maintain euglycemia for 2 hours. At the same time, an IV infusion of either saline (SAL) or C-peptide (CPEP) was started. After this euglycemic period, the insulin and SAL/CPEP infusions were continued for another 2 hours, but the glucose was allowed to fall to approximately 50 mg/dL. In response to euglycemic-hyperinsulinemia, glucagon secretion decreased in SAL but remained unchanged from the basal period in CPEP condition. During hypoglycemia, glucagon secretion in CPEP was 2 times higher than SAL, and this increased net hepatic glucose output and reduced the amount of exogenous glucose required to maintain glycemia. These data suggest that the presence of C-peptide during IV insulin infusion can preserve glucagon secretion during euglycemia and enhance it during hypoglycemia, which could explain why T1D patients with residual insulin secretion are less susceptible to hypoglycemia.

1 December 2019 in The Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
SPShivani J. Patel
Shivani J. Patel
LFLeslie Farrell
Leslie Farrell
DDDominick DeBlasio
Dominick DeBlasio
ABAshlee K. Bolger
Ashlee K. Bolger
JBJennifer M. Brady
Jennifer M. Brady
FRFrancis J. Real
Francis J. Real
Clinical training in medical school education has undergone many changes in recent years. Direct observation and hands-on teaching of physical skills by faculty, although recognized as optimal by students, has declined owing to increased patient turnover, heightened concerns related to patients' privacy, and increased reliance on technology for diagnostics.1 x 1 Williams, K.N., Ramani, S., Fraser, B., and Orlander, J.D. Improving bedside teaching: findings from a focus group study of learners. Acad Med. 2008; 83: 257–264 Google Scholar See all References , 2 x 2 Nair, B.R., Coughlan, J.L., and Hensley, M.J. Student and patient perspectives on bedside teaching. Med Educ. 1997; 31: 341–346 Google Scholar See all References , 3 x 3 Peters, M. and Ten Cate, O. Bedside teaching in medical education: a literature review. Perspect Med Educ. 2014; 3: 76–88 Google Scholar See all References , 4 x 4 Crumlish, C.M., Yialamas, M.A., and McMahon, G.T. Quantification of bedside teaching by an academic hospitalist group. J Hosp Med. 2009; 4: 304–307 Google Scholar See all References Furthermore, medical educators may feel overwhelmed trying to balance clinical duties with the growing number of learners seeking education at academic medical centers.5 x 5 Nation's Medical Schools increase enrollment by 25 percent since 2002. www.aamc.org/newsroom/newsreleases/459956/enrollment_survey_05052016.html; 2016. Google Scholar See all References